Influence how the body stores and burns energy, potentially raising calorie expenditure
Rob Berberian builds individualized treatment plans for patients throughout Newport Beach, Orange County, Los Angeles, and California combining the following approaches
It means we do not have the quality of evidence needed to make confident claims about efficacy
The recent FLOW trial with semaglutide in patients with chronic kidney disease and T2DM, with a composite of major kidney disease events as the primary outcome, showed significant reductions in both cardiovascular mortality (HR 0.71
Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
Its approval followed extensive clinical trials demonstrating safety, bioavailability, GLP-1 receptor engagement, and meaningful weight-related outcomes